Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobimetinib in Histiocytoses (COBRAH)
NCT04007848Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cobimetinib in Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), Rosai-Dorfman disease (RDD), sponsored by Assistance publique - Hôpitaux de Paris. Started Jul 2019; status: completed.
02
Drugs
cobimetinib
03
Conditions
Langerhans cell histiocytosis (LCH)Erdheim-Chester disease (ECD)Rosai-Dorfman disease (RDD)
Beyond the preview
Go deeper on NCT04007848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04007848.